Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.

被引：4

作者：

O'Malley, David M.

Martin, Lainie P.

Gilbert, Lucy

Vergote, Ignace

Matulonis, Ursula A.

Birrer, Michael J.

Castro, Cesar Martin

Malek, Karim S.

Gonzalez-Martin, Antonio

Moore, Kathleen N.

机构：

[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[3] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[4] Univ Ziekenhuizen UZ Leuven, Leuven, Belgium

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[7] Harvard Med Sch, Massachusetts Gen Hosp, Reading, MA USA

[8] Med Onc & Hem PC, Waltham, MA USA

[9] GEICO, Madrid, Spain

[10] Clin Univ Navarra, Madrid, Spain

[11] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.5549

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5549

引用

页数：2